1. Chiralit drug design development;Patel,2004
2. Oxybutynin extended release for the management of overactive bladder: a clinical review;Arisco;Drug Des. Dev. Ther.,2009
3. Oxybutynin: an overview of the available formulations;McCrery;Ther. Clin. Risk Manage.,2006
4. A comparative review of oxybutynin chloride formulations: pharmacokinectics and therapeutic efficacy in overactive bladder;Kennelly;Rev. Urol.,2010
5. DITROPAN™ (oxybutynin chloride) Product Information. Sanofi-Aventis, One Onslow, Guildford, Surrey, UK, http://products.sanofi.com.au/aus_pi_ditropan.pdf.